NSD2 aggravates metabolic dysfunction-associated steatotic liver disease progression by suppressing TFEB-mediated autophagy-lysosomal pathway
ChIP-seq / ATAC-seq (genome binding and open chromatin) · human · 2 samples
- What it is
- ChIP-seq / ATAC-seq (genome binding and open chromatin)Where proteins bind the genome, or which regions are open and active.
- Organism
- Homo sapiens (human)
- Samples
- 2 samples
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE287554_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: Look for peak files (.bed, .narrowPeak) and signal tracks (.bigWig) among the supplementary files; the raw reads are on ENA.
Also filed as BioProject PRJNA1213738 and SRA study SRP558690. Searching any of these in the dataset finder brings you back here.
The sample list for this study is not cached yet. Press Load samples and it will be fetched from NCBI.
+ 2 more — browse all 2 samples with per-sample file links →
- GSE303090 Mature Polarized Hepatocyte Organoids Derived from Human Embryonic Stem Cells for Modeling the Pathogenesis and Progression of Metabolic Dysfunction-Associated Steatotic Liver Disease and Therapeutic Drug Screening 12 samples shares dysfunction-associated, progression, steatotic
- GSE269929 Single nucleus RNA-sequencing integrated into risk variant colocalization discovers 17 cell-type-specific abdominal obesity genes for metabolic dysfunction-associated steatotic liver disease [ATAC-seq] 24 samples shares dysfunction-associated, steatotic
- GSE281797 Transcriptomic profiles of liver biopsies in obese patients with metabolic dysfunction-associated steatotic liver disease 94 samples shares dysfunction-associated, steatotic
- GSE282757 Evidence of a gut-adipose-liver axis: microbiota encroachment in metabolic dysfunction-associated steatotic liver disease 39 samples shares dysfunction-associated, steatotic
- GSE244832 Multi-Modal Comparison of human Hepatic Stellate Cells identifies novel therapeutic targets for Metabolic Dysfunction-Associated Steatotic Liver Disease 36 samples shares dysfunction-associated, steatotic
- GSE318806 P21+TREM2+-Senescent Macrophages Fuel Inflammaging and Metabolic Dysfunction-Associated Steatotic Liver Disease. [Blood] 9 samples shares dysfunction-associated, steatotic
- GSE269926 Single nucleus RNA-sequencing integrated into risk variant colocalization discovers 17 cell-type-specific abdominal obesity genes for metabolic dysfunction-associated steatotic liver disease [scRNA-seq] 8 samples shares dysfunction-associated, steatotic
- GSE273490 Selective NSD2 Inhibition Reveals an Epigenetic Vulnerability of KRAS-Driven Cancers [CUT&Run] 120 samples shares nsd2
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.